A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Main Article Content

Andrew Blauvelt
Joseph F Fowler, Jr.
Ellen Schuck
Julia Jauch
Heike Woehling
Craig L Leonardi

Keywords

adalimumab, biosimilar, psoriasis

Abstract

Abstract Not Available